Assertio Holdings, Inc. (ASRT) Stock Forecast
Data as of Aug 7, 2026Healthcare · Current price $23.50 (—)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
ASRT vs Sector & Market
| Metric | ASRT | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 3.00 | 2.25 | 2.42 |
| Analyst Count | 4 | 8 | 18 |
| Target Upside | -3.6% | +16316.2% | +17.2% |
| P/E Ratio | -3.93 | 3.41 | 35.26 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $111M | $114M | $116M | 3 |
| 2027-12-31 | $127M | $130M | $133M | 2 |
| 2028-12-31 | $143M | $147M | $150M | 1 |
| 2029-12-31 | $155M | $159M | $163M | 1 |
| 2030-12-31 | $163M | $167M | $171M | 1 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-0.18 | $-0.17 | $-0.17 | 2 |
| 2027-12-31 | $1.91 | $1.97 | $2.03 | 1 |
| 2028-12-31 | $6.11 | $6.32 | $6.51 | 1 |
| 2029-12-31 | $7.21 | $7.46 | $7.68 | 1 |
| 2030-12-31 | $8.11 | $8.39 | $8.64 | 1 |
Frequently Asked Questions
What is the analyst consensus for ASRT?
The consensus among 4 analysts covering Assertio Holdings, Inc. (ASRT) is Hold with an average price target of $22.65.
What is the highest price target for ASRT?
The highest analyst price target for ASRT is $23.50.
What is the lowest price target for ASRT?
The lowest analyst price target for ASRT is $21.80.
How many analysts cover ASRT?
4 analysts have issued ratings for Assertio Holdings, Inc. in the past 12 months.
Is ASRT a buy or sell right now?
Based on 4 analyst ratings, ASRT has a consensus rating of Hold (3.00/5) with a -3.6% upside to the consensus target of $22.65.
What are the earnings estimates for ASRT?
Analysts estimate ASRT will report EPS of $-0.17 for the period ending 2026-12-31, with revenue estimated at $114M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.